Drug rash with eosinophilia and systemic symptoms
Drug rash with eosinophilia and systemic symptoms | |
---|---|
Other names | Drug reaction with eosinophilia and systemic symptoms, DRESS, DRESS syndrome, drug-induced hypersensitivity syndrome, DIHS, drug hypersensitivity syndrome, DHS, drug-induced delayed multiorgan hypersensitivity syndrome, DIDMOHS, (formerly) drug-induced pseudolymphoma |
Specialty | Immunology, dermatology |
Drug rash with eosinophilia and systemic symptoms or drug reaction with eosinophilia and systemic symptoms (DRESS), also termed drug-induced hypersensitivity syndrome (DIHS), is a rare reaction to certain medications. It involves primarily a widespread skin rash, fever, swollen lymph nodes, and characteristic blood abnormalities such as an abnormally high level of eosinophils, low number of platelets, and increased number of atypical white blood cells (lymphocytes). However, DRESS is often complicated by potentially life-threatening inflammation of internal organs and the syndrome has about a 10% mortality rate.[1] Treatment consists of stopping the offending medication and providing supportive care. Systemic corticosteroids are commonly used as well but no controlled clinical trials have assessed the efficacy of this treatment.[2]
DRESS is classified as one form of severe cutaneous adverse reactions (SCARs). In addition to DRESS, SCARs includes four other drug-induced skin reactions: the Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Stevens–Johnson/toxic epidermal necrolysis overlap syndrome (SJS/TEN) and acute generalized exanthematous pustulosis (AGEP). The SCARs disorders have similar disease mechanisms. New strategies are in use or development to screen individuals at risk for DRESS to aid them in avoiding medications that increase the risk of DRESS. Alternative medications are used in all individuals testing positive for these predispositions.[3]
Prior to 1996, there were numerous reports on individuals presenting with a medication-induced disorder now recognized as the DRESS syndrome. For example, anticonvulsants in the 1930s, phenytoin in 1950, and other medications in the ensuing years were reported to do so. The reports often named the disorder based on the medication evoking it, e.g. the anticonvulsant hypersensitivity syndrome, allopurinol hypersensitivity syndrome, and dapsone hypersensitivity syndrome.[4] In 1996, however, the term DRESS syndrome was coined in a report attempting to simplify the terminology and consolidate these various clearly related syndromes into a single underlying disorder.[5][6]
Signs and symptoms
The symptoms of DRESS syndrome usually begin 2 to 6 weeks but uncommonly up to 8–16 weeks after exposure to an offending drug. Symptoms generally include fever, an often itchy rash which may be
The following table gives the percentages for organ involvement and blood abnormalities found in individuals with the DRESS syndrome based on various studies. There are large variations in the percentages found in different studies and populations.[9][4][10][11][12]
Organ | Percentage involvement | Comment | Blood abnormality | Percentage involvement | Comment | |
---|---|---|---|---|---|---|
Liver | 59-100% | >90% if based on high blood levels of ALT |
Eosinophilia | 30-95% | usually seen in >66% of cases | |
Kidney | 8-40% | >40% if based on high levels of BUN or creatinine | Atypical blood lymphocytosis | 27-67% | - | |
Lung | 5-33% | usually resolves | Lymphocytosis | ~3% | - | |
Heart (hypersensitivity reaction) | 2-15% | generally not life-threatening | Leukocytosis | up to 100% | due to eosinophilia and/or lymphocytosis | |
Heart (necrotizing eosinophilic myocarditis) | 2-15% | mortality> 50% | Thrombocytopenia | 3% | Thrombocytopenia may precede and not be due to DRESS syndrome[13] | |
Nervous system | ~5% | usually resolves | Elevated ESR | ~60-70% | marker of systemic inflammation | |
Pancreas | ~5% | may result in diabetes | Elevated C-reactive protein | ~60% | marker of systemic inflammation |
No gold standard exists for diagnosis, and at least two diagnostic criteria have been proposed viz., the RegiSCAR criteria [14] and the Japanese consensus group criteria.[15] These two sets of criteria are detailed in the following table.
RegiSCAR inclusion criteria for DRESS syndrome: 3 of the 4 starred criteria are required for diagnosis | Japanese consensus group diagnostic criteria for DIHS: 7 criteria are needed for diagnosis of DIHS or the first 5 criteria required for diagnosis of atypical DIHS. |
---|---|
Hospitalization | pruritic, macular erythema containing papules, pustules or vesicles (generally a Maculopapular rash), developing >3 weeks after starting suspected drug |
Reaction suspected to be drug-related | Prolonged clinical symptoms 2 weeks after discontinuation of the suspected drug |
Acute Rash* | Fever > 38 °C |
Fever > 38 °C* | Liver abnormalities (ALT > 100 U/L) or other organ involvement |
Lymphadenopathy in at least two sites* | Leukocyte abnormalities
|
Involvement of at least one internal organ* | Leukocytosis ( > 11 x 109/l) |
Blood count abnormalities (lymphopenia or lymphocytosis*, eosinophilia*, thrombocytopenia*) | Atypical lymphocytosis (>5%) |
Severe nerve pain | Lymphadenopathy |
Human herpesvirus 6 reactivation |
Causes
Medications
Drugs that commonly induce DRESS syndrome arranged according to intended clinical action include the following:[4][16][17][18][19][20][21]
- Anticonvulsants: Carbamazepine, lamotrigine, phenobarbital, phenytoin, oxcarbazepine, gabapentin, primidone
- Antibacterial: Amoxicillin, ampicillin, azithromycin, levofloxacin, minocycline, piperacillin/tazobactam combination, vancomycin, streptomycin
- rifampin
- Anti-retroviral: Abacavir, nevirapine
- Anti-hepatitis C: Boceprevir, telaprevir
- ,
- Other drugs: heart arrhythmias), omeprazole (treatment for gastroesophageal reflux and peptic ulcer), Strontium ranelate (osteoporosis treatment), Chinese herbal medicine.
Medications associated with the development of DRESS are often popular, widely used, and/or clinically important for the control of certain diseases. This is evident in the most commonly cited medications that cause the DRESS viz.,
Genetics
Studies have found that certain populations that express particular serotypes (i.e. alleles) of HLA-A, HLA-B, and/or HLA-C have an increased risk of developing the DRESS syndrome in response to specific medications. These associations include the following:[4][22]
- Carbamazepine: Chinese, Koreans, Japanese, and European individuals who express the HLA serotype (i.e. allele) termed also have increased risks of developing it in response to Carbamazepine.
- Phenytoin: HLA-DRB1*16:02serotypes have higher risks of developing the syndrome in response to phenytoin.
- Dapsone: Han Chinese individuals expressing the HLA-B13:01serotype have a higher risk (7.8%) of developing the DRESS syndrome in response to dapsone.
- Allopurinol: Han Chinese, Korean, Thai, and European individuals expressing the HLA-B58:01serotype have a higher incidence of developing the syndrome in response to allopurinol.
- Nevirapine: Africans, Asians, and Europeans expressing HLA-C04 serotype have higher incidences of developing the syndrome in response to nevirapine.[23]
- Abacavir: European and African individuals expressing the HLA-B57:01 serotype have a higher incidence (55%) of developing the syndrome in response to abacavir.[24]
- Vancomycin: European individuals carrying HLA-A*32:01 have an approximately 20% chance of developing DRESS syndrome after ≥ 2 weeks of vancomycin [25]
Pathophysiology
Human leukocyte antigens
Like other drug-induced SCARs disorders, the DRESS syndrome is a
Like other SCARs-inducing drugs, DRESS syndrome-inducing drugs or their metabolites stimulate CD8+ T or CD4+ T cells to initiate autoimmune responses. Studies indicate that the mechanism by which a drug or its metabolites accomplishes this stimulation involves subverting the
T-cell receptors
A drug or its metabolite may also stimulate CD8+ T or CD4+ T cells to initiate autoimmune responses by directly binding to the T-cell receptors on these T cells. Again, this binding appears to develop only on certain T-cell receptors. Since the genes for these receptors are highly edited, i.e. altered to encode proteins with different amino acid sequences, and since the human population may express more than 100 trillion different (i.e. different amino acid sequences) T-cell receptors while an individual express only a fraction of these, a drug's or its metabolite's ability to induce the DRESS syndrome by interacting with a T-cell receptor is limited to those individuals whose T cells express a T-cell receptor(s) that can interact with drug or its metabolite.[28][22] Thus, only rare individuals are predisposed to develop a SCARs disorder in response to a particular drug on the basis of their expression of specific cell receptor types.[30] While the evidence supporting these ideas is limited, one study identified the preferential presence of the TCR-V-b and complementarity-determining region 3 in T-cell receptors found on the T cells in the blisters of patients with allopurinol-induced DRESS syndrome. This finding is compatible with the notion that specific types of T-cell receptors are involved in the development of specific drug-induced SCARs.[31]
ADME
Variations in
Viral reactivation
During the progression of the DRESS syndrome certain viruses that previously infected an individual and then became
Preventative
Currently, screening individuals for the expression of certain HLA
- Allopurinol: The American College of Rheumatology guidelines for the management of gout recommend HLA-B*58:01 screening before allopurinol treatment. This is provided in many medical centers in Taiwan, Hong Kong, Thailand, and Mainland China.
- Abacavir: The USA Food and Drug Administration and recommends screening for HLA-B*57:01 in the treatment of HIV with abacovir in Caucasian populations. This screening is widely implemented. It has also been suggested that all individuals found to express this HLA serotype avoid treatment with abacovir.
Current trials are underway to evaluate the ability of genetic screening to prevent the DRESS syndrome for dapsone and HLA-B*13:01 in China and Indonesia. Similar trials are underway in Taiwan to prevent phenytoin-induced DRESS syndrome in individuals expressing the CYP2C9*3 allele of CYP2C9 as well as a series of HLA alleles.[35]
Treatment
Immediate discontinuance of the offending drug or drug(s) is the first and critical step in treating any SCARs disorder. In the past, the mainstay treatment of severe cases of DRESS syndrome was the use, often at high-dosage, of systemic
Terminology
DRESS syndrome is one of several terms that have been used to describe a severe idiosyncratic reaction to a drug that is characterized by a long latency of onset after exposure to the offending medication, a rash, involvement of internal organs, hematologic abnormalities, and systemic illness. Other synonymous names and acronyms include drug-induced hypersensitivity syndrome (DIHS or DHiS), anticonvulsant hypersensitivity syndrome, drug-induced delayed multiorgan hypersensitivity syndrome, drug-induced pseudolymphoma, anticonvulsant hypersensitivity syndrome, allopurinol hypersensitivity syndrome, dapsone syndrome, and dapsone hypersensitivity syndrome.[1][4][5][6]
See also
- Severe cutaneous adverse reactions
- Adverse drug reaction
- Drug allergy
- Drug intolerance
- Drug tolerance
- List of skin conditions
- Eosinophilic myocarditis associated with the DRESS syndrome
References
- ^ S2CID 16048518.
- S2CID 34572606.
- ^ PMID 28256714.
- ^ PMID 28598363.
- ^ PMID 9069593.
- ^ S2CID 27319054.
- PMID 28665896.
- PMID 27996289.
- ^ S2CID 10549742.
- PMID 20713773.
- PMID 26534757.
- PMID 24388810.
- PMID 26120067.
- S2CID 32299525.
- S2CID 33786375.
- PMID 15358574.
- ^ "Tetracycline (doxycycline, minocycline)".
- PMID 16259349. Archived from the original(PDF) on 2020-11-28. Retrieved 2009-02-03.
- ^ "Ziprasidone (Marketed as Geodon and Generics): Drug Safety Communication - Rare But Potentially Fatal Skin Reactions". Food and Drug Administration. 11 December 2014.
- PMID 22525393.
- ^ "Olanzapine: Drug Safety Communication - FDA Warns About Rare But Serious Skin Reactions". Food and Drug Administration. 10 May 2016.
- ^ PMID 28345177.
- PMID 28819312.
- PMID 18256392.
- PMID 30776417.
- ^ S2CID 333724.
- PMID 27472323.
- ^ S2CID 9506967.
- S2CID 4436573.
- ^ PMID 27960170.
- ^ S2CID 9183824.
- S2CID 45524211.
- S2CID 46796285.
- PMID 28346659.
- ^ PMID 27854302.